|
EUROVAC-II - European vaccine effort against hiv/aids - ii (LIFE QUALITY) (2001-11-01 - 2005-04-30)
(»add to infobox)
 
|
Heather MARSHALL-HEYMAN,
Louise J. GUNNING-SCHEPERS,
Jeffrey ALMOND,
Bruno ANDRAL,
David TATCHER,
Luigi M. VERZE,
Rodney SORTWELL,
Lynne COX,
Gilles BLOCK,
Ian VINEY,
Jean-François CARMIER,
Christian BLOMEYER,
Jacques BESSON
|
|
KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden),
ACADEMIC MEDICAL CENTRE BY THE UNIVERSITY OF AMSTERDAM (NL326 - Groot-Amsterdam) (Netherlands),
AVENTIS PASTEUR SA (FR716 - Rhône) (France),
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France),
COBRA THERAPEUTICS LTD (UK722 - Staffordshire) (Great Britain),
FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR (ITC45 - Milano) (Italy),
HUNTINGDON LIFE SCIENCES LTD (UK330 - Lincolnshire) (Great Britain),
IMPERIAL COLLEGE LONDON (UK550 - Greater London) (Great Britain),
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR421 - Bas-Rhin) (France),
MEDICAL RESEARCH COUNCIL (UK550 - Greater London) (Great Britain),
TRANSGENE SA (FR421 - Bas-Rhin) (France),
UNIVERSITAET REGENSBURG (DE238 - Regensburg, Landkreis) (Germany),
UNIVERSITY OF LAUSANNE (CH011 - Vaud) (Switzerland) |
| BUDGET: | 4.961.127 € |
| FUNDING: | 2.999.997 € |
| INSTRUMENT: | Demonstration Contracts |
| PROGRAMME: | LIFE QUALITY |
|
|
|
HIV-1 and AIDS are spreading in Africa and Asia at unprecedented speed. A vaccine against HIV-1/AIDS is urgently needed. Vaccine candidates that show most promise in simian AIDS models are based on a prime-boost strategy, applying naked DNA or alphaviruses as prime and pox viruses as boost. The objectives of the EuroVac- II project are to demonstrate in a phase I trial of humans: firstly the ability of Semliki Forest virus (SFV) to prime anti-HIV immune responses, - compared to the attenuated poxvirus NYVAC -, using a recombinant gp140 protein boost; and secondly the ability of SFV priming, - using DNA priming as benchmark -, to improve the immune responses elicited by NYVAC + rgp140 vaccination. This design will provide conclusions concerning the relative immunogenicity of different prime-boost strategies. The HIV-1 genes used are recovered from a primary isolate belonging to HIV-1 subtype C, the most frequent cause of AIDS worldwide. The choice of genes (gag, pol, nef) other than envelope is based on the frequency of HIV-specific T-cell responses in long-term asymptomatic HIV infected individuals.
|
| PERSONS (13/13) |
|
Heather MARSHALL-HEYMAN (Contact / KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden))
Louise J. GUNNING-SCHEPERS (Contact / ACADEMIC MEDICAL CENTRE BY THE UNIVERSITY OF AMSTERDAM (NL326 - Groot-Amsterdam) (Netherlands))
Jeffrey ALMOND (Contact / AVENTIS PASTEUR SA (FR716 - Rhône) (France))
Bruno ANDRAL (Contact / CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France))
David TATCHER (Contact / COBRA THERAPEUTICS LTD (UK722 - Staffordshire) (Great Britain))
Luigi M. VERZE (Contact / FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR (ITC45 - Milano) (Italy))
Rodney SORTWELL (Contact / HUNTINGDON LIFE SCIENCES LTD (UK330 - Lincolnshire) (Great Britain))
Lynne COX (Contact / IMPERIAL COLLEGE LONDON (UK550 - Greater London) (Great Britain))
Gilles BLOCK (Contact / INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR421 - Bas-Rhin) (France))
Ian VINEY (Contact / MEDICAL RESEARCH COUNCIL (UK550 - Greater London) (Great Britain))
Jean-François CARMIER (Contact / TRANSGENE SA (FR421 - Bas-Rhin) (France))
Christian BLOMEYER (Contact / UNIVERSITAET REGENSBURG (DE238 - Regensburg, Landkreis) (Germany))
Jacques BESSON (Contact / UNIVERSITY OF LAUSANNE (CH011 - Vaud) (Switzerland))
| RELATED NAVIGATION AREA(S) (2/2) |
|
FP5 Life Quality
Infectiology
|
|
|
|
